Does Cosentyx Reduce Vaccine Efficacy?
Cosentyx (secukinumab), an IL-17 inhibitor for psoriasis and other conditions, impairs immune responses to some vaccines, particularly live vaccines. The prescribing information warns against live vaccines during treatment due to reduced efficacy and infection risk.[1] For inactivated vaccines like most COVID-19 shots (e.g., Pfizer, Moderna), studies show diminished antibody responses when Cosentyx is injected near the vaccine site or systemically active.
A phase 4 trial (CAIN457A2316) found that psoriasis patients on Cosentyx had 20-30% lower seroprotection rates against influenza vaccine antigens compared to placebo, regardless of injection site.[2] Local interference at injection points isn't specifically proven, but subcutaneous overlap (e.g., both in deltoid) may amplify this via transient cytokine suppression at the site.
How Does Cosentyx Work and Why Vaccines?
Cosentyx blocks IL-17A, dampening T-cell driven inflammation. Vaccines rely on IL-17 signaling for robust antibody production and memory B-cells. Injection-site proximity could locally blunt dendritic cell activation, but systemic effects dominate—efficacy drops persist even with distant administration.[1][3]
Which Vaccines Are Most Affected?
| Vaccine Type | Impact with Cosentyx | Recommendation |
|--------------|----------------------|---------------|
| Live (e.g., MMR, varicella, yellow fever) | High risk of failure/infection | Avoid during treatment |
| Inactivated/non-live (e.g., flu, COVID-19, pneumococcal) | Moderate reduction in titers (15-40%) | Administer, but test response if high-risk |
| Recombinant (e.g., shingles, HPV) | Milder impact, but monitor | Preferred over live options |
COVID-19 vaccines show specific waning: one study reported 25% lower neutralizing antibodies in Cosentyx users vs. controls 28 days post-dose.[4]
Timing and Injection Site Tips
Administer vaccines before starting Cosentyx if possible—hold dosing 4 weeks pre-vaccination for optimal response.[1] Use opposite arms or distant sites (e.g., thigh) to minimize local interference. Post-vaccination, resume Cosentyx after 2-4 weeks. No data shows complete avoidance of impact via site separation.
Patient Reports and Real-World Data
Rheumatology forums and FDA adverse events note breakthrough infections post-vaccination in Cosentyx users, like shingles despite vaccine.[5] A 2023 psoriasis registry (PsoBest) linked ongoing biologics to 18% lower flu vaccine seroconversion.[6]
Alternatives for Vaccinated Patients
Switch to IL-23 inhibitors (e.g., Tremfya) or JAK inhibitors (e.g., Rinvoq), which preserve better vaccine responses—up to 90% seroprotection vs. Cosentyx's 60-70%.[7] Consult immunology for high-risk cases.
[1] Cosentyx Prescribing Information (Novartis, 2023)
[2] PubMed: Secukinumab and vaccine response (NCT01796184), 2018
[3] Nature Reviews Rheumatology: Biologics and vaccines, 2021
[4] Annals of Rheumatic Diseases: COVID vaccines in IL-17 inhibitors, 2022
[5] FDA FAERS database query: Cosentyx + vaccine, accessed 2024
[6] JAMA Dermatology: PsoBest registry, 2023
[7] Rheumatology: Comparative vaccine immunogenicity, 2023